Japan· JP-1319757Q1060
ビマトプロスト
A bimatoprost product containing ビマトプロスト, registered in Japan by 東亜薬品, on the national reimbursement list. The same ATC class is registered in 19 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Bimatoprost is registered in 19 of 19 countries.
Countries holding a registration under ATC S01EE03 (bimatoprost), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 11 of them publish a price we can compare per daily dose
Bimatoprost · ATC S01EE03
19 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Germany
- Icelandprice
- Ireland
- Italyprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Spainprice
- Sweden
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- ビマトプロスト
- Manufacturer
- 東亜薬品
- Country
- Japan (JP)
- ATC code
- S01EE03
- ATC class
- Bimatoprost
- Defined daily dose
- 0.1 ml, AT
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
89 interactions on record for bimatoprost.
Graded by severity as the source publishes them — 89 info. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Bimatoprost · interactions on record
89 records
Same class
Other records under S01EE03
Bimatoprost, as other registers publish it.
- GermanyAmirioxSifi S.P.A.
- FranceAMIRIOX 0,3 mg/mL, collyre en solutionSIFI (ITALIE)
- ItalyAMIRIOX*collirio 1 flaconcino 3 ml 0,3 mg/mlSIFI SpA
- ItalyBIALVIZGENETIC S.P.A.
- ItalyBIMADOCDOC GENERICI S.R.L.
- ItalyBIMADOCDOC GENERICI S.R.L.
- NetherlandsBimagan 0,1 mg/ml, oogdruppels, oplossingS.C. Rompharm Company S.R.L.
- NetherlandsBIMAGAN 0,3 mg/ml oogdruppels, oplossingS.C. Rompharm Company S.R.L.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dbe52a06-c76e-4e57-8e26-291e08aa02bf GET /v1/drugs/dbe52a06-c76e-4e57-8e26-291e08aa02bf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "０．０３％１ｍＬ",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "1319757Q1060",
"category": "外用薬",
"price_yen": 125.9,
"generic_name": "ビマトプロスト",
"product_name_jp": null,
"therapeutic_class": "1319",
"transitional_expiry": null
}See everything about bimatoprost.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.